Effect of Semaglutide on Embryo Quality in Overweight and Obese Patients Undergoing In Vitro Fertilization.
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexFemale
Age18-38
SponsorFundacion Dexeus
About this trial
This is a randomized, controlled clinical trial with a two-sided superiority hypothesis. The study evaluates whether a 12-week pre-treatment with semaglutide prior to ovarian stimulation improves the number of good-quality blastocysts in overweight and obese women undergoing in vitro fertilization (IVF), compared to no pre-treatment.
Eligibility criteria
Qualifiers
≤ 38 years
AMH >= 1 ng/mL or AFC >= 6
Body mass index (BMI) between 27 kg/m2 and 40 kg/m2
Scheduled for IVF with freeze-all strategy
Disqualifiers
Severe male factor (sperm concentration <5M/mL)
Type 2 diabetes mellitus
Prior use of GLP-1 Ras within the past year
Uncontrolled thyroid disorders
Trial design
Treatments tested in this trial
- Semaglutide
- No pre-treatment
Treatment groups
62 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov